Drug
Terbogrel Low Dose
Terbogrel Low Dose: highest development phase Phase 2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Terbogrel low dose NCT02223481 | Phase 2 | Hypertension, Pulmonary |
Latest
No recent events.
Follow Terbogrel Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.